EUVIMEDOpdag EUVIMED
Leitlinie

Implications of a new guideline on treating gestational diabetes in Denmark

Nina Lund Larsen, Line Barner Dalgaard, Lene Ring Madsen

Danish Medical Journal · 2025

DOI: 10.61409/a04250331 ↗

At a glance

Leitlinie in Danish Medical Journal, 2025. Written by Nina Lund Larsen and 2 co-authors. Institution: Department of Gynaecology and Obstetrics, Gødstrup Hospital. Major MEDLINE topics: Diabetes, Gestational, Insulin, Practice Guidelines as Topic, Hypoglycemic Agents. 17 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

INTRODUCTION. In late 2023, the Danish national guideline on treatment of gestational diabetes mellitus (GDM) introduced tighter glucose control to prevent foetal and maternal complications. The change was expected to lead to an increased use of insulin therapy in GDM treatment. This study aimed to evaluate insulin usage and obstetric outcomes when adhering to the new guideline. METHODS. This retrospective cohort study evaluated women diagnosed with GDM (n = 67) from May to October 2024 at Gødstrup Hospital, compared with women diagnosed with GDM (n = 46) in a three-month period in 2023 before implementation of the new guideline. Data on maternal age, pre-pregnancy BMI, ethnicity, education, oral glucose tolerance test 2-h values, insulin treatment, induction of labour and foetal characteristics were collected. RESULTS. The number of women treated with insulin increased from 26% (2023) to 58% (2024), p < 0.01, but the maximum insulin dose did not change (0.42 IU/kg/day). Birthweight and birthweight z-scores were comparable. In 2024, induction of labour was more prevalent (63% versus 39%, p < 0.01) without a corresponding rise in obstetric and perinatal complications. CONCLUSIONS. Implementation of the new GDM guideline increased the number of women requiring insulin treatment but did not affect the maximum dose of insulin per kg. The increase in insulin treatment led to a higher labour induction rate, increasing the workload for the obstetric department. Our data showed no decrease in birthweight or the incidence of large-for-gestational-age offspring. FUNDING. None. TRIAL REGISTRATION. Not relevant.

Subjects

MeSH terms (MEDLINE)

Diabetes, GestationalInsulinPractice Guidelines as TopicHypoglycemic AgentsGuideline AdherenceHumansFemalePregnancyDenmarkRetrospective StudiesAdultLabor, InducedPregnancy OutcomeGlucose Tolerance TestBirth Weight

Substances

InsulinHypoglycemic Agents

Authors and institutions

  • Department of Gynaecology and Obstetrics, Gødstrup Hospital.
  • Faculty of Health, Aarhus University.
  • Endocrinology Section, Department of Medicine, Gødstrup Hospital.
  • Steno Diabetes Center Aarhus, Aarhus University Hospital.
  • Danish Diabetes and Endocrine Academy, Odense University Hospital, Denmark.

Cite

APA

Larsen, N. L., Dalgaard, L. B., & Madsen, L. R. (2025). Implications of a new guideline on treating gestational diabetes in Denmark. Danish Medical Journal. https://doi.org/10.61409/a04250331

Vancouver

Larsen NL, Dalgaard LB, Madsen LR. Implications of a new guideline on treating gestational diabetes in Denmark. Danish Medical Journal. 2025. doi:10.61409/a04250331

BibTeX
@article{Larsen2025,
  author = {Larsen, Nina Lund and Dalgaard, Line Barner and Madsen, Lene Ring},
  title = {Implications of a new guideline on treating gestational diabetes in Denmark},
  journal = {Danish Medical Journal},
  year = {2025},
  doi = {10.61409/a04250331}
}
Start for free →